On the US stock charts, Mineralys Therapeutics, Inc. (NASDAQ: MLYS) had a 12.02% increase in stock price during Friday’s extended session, closing at $9.69. The regular session saw a stabilization of the Mineralys stock, with a mere 0.23% rise to close at $8.65. Following the news of a new appointment, MLYS stock shot up.
Minji Kim, Ph.D. has been appointed Chief Business Officer of Mineralys (MLYS). Chief Financial Officer Adam Levy will continue to serve in this capacity. Mineralys has chosen to divide the responsibilities of Chief Financial Officer and Chief Business Officer into two due to the company’s growing activities.
Dr. Kim has a proven track record of seeing and seizing strategic opportunities to create value for a number of businesses. With its whole executive team in place at the beginning of 2024, MLYS will be better equipped to pursue its late-stage clinical development of lorundrostat as a therapy for aldosterone-dependent diseases such hypertension and chronic renal disease.
Lorundrostat has a great deal of potential to meet unmet needs in patients with diseases associated with abnormally elevated aldosterone, as evidenced by the several clinical milestones that are expected for the drug over the next 12 to 18 months and the present status of the in progress pivotal clinical development program.
Dr. Kim has over twenty years of expertise in scientific research, strategic leadership, and commercial growth. She has worked in a variety of therapeutic and technical sectors for biotech businesses both domestically and internationally during her career. She got many products into the pipeline while serving as General Manager at Affamed Digital and Chief Business Officer at Affamed Therapeutics before joining Mineralys.
In order to assess the safety and effectiveness of lorundrostat as an add-on therapy to recommended background medication for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), Mineralys recently dosed the first participant in the Launch-HTN pivotal study.
